Patents by Inventor John Wesolowski

John Wesolowski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240086059
    Abstract: User interface methods and systems are provided for interfacing with a plurality of objects in three-dimensional virtual environment providing for a medical imaging workspace. A method includes identifying one of a plurality of objects arranged in a three-dimensional virtual medical imaging workspace as a user-intended contextual selection based on detected gaze tracking information and establishing a command context based on the identified object. The command context comprises voice-activated commands, gesture-activated commands, or a combination thereof. The method further includes activating an object-specific action based on a detected voice or gesture command.
    Type: Application
    Filed: September 6, 2023
    Publication date: March 14, 2024
    Inventors: John Corydon Huffman, Michal Wesolowski
  • Publication number: 20090088561
    Abstract: Disclosed are methods for the genetic construction and expression of antibody-based fusion proteins with enhanced circulating half-lives. The fusion proteins of the present invention lack the ability to bind to immunoglobulin Fc receptors, either as a consequence of the antibody isotype used for fusion protein construction, or through directed mutagenesis of antibody isotypes that normally bind Fc receptors. The fusion proteins of the present invention may also contain a functional domain capable of binding an immunoglobulin protection receptor.
    Type: Application
    Filed: October 2, 2008
    Publication date: April 2, 2009
    Applicant: Merck Patent GmbH
    Inventors: Stephen Gillies, Kin-Ming Lo, Yan Lan, John Wesolowski
  • Publication number: 20060194952
    Abstract: Disclosed are methods for the genetic construction and expression of antibody-based fusion proteins with enhanced circulating half-lives. The fusion proteins of the present invention lack the ability to bind to immunoglobulin Fc receptors, either as a consequence of the antibody isotype used for fusion protein construction, or through directed mutagenesis of antibody isotypes that normally bind Fc receptors. The fusion proteins of the present invention may also contain a functional domain capable of binding an immunoglobulin protection receptor.
    Type: Application
    Filed: May 9, 2006
    Publication date: August 31, 2006
    Applicant: EMD Lexigen Research Center Corp.
    Inventors: Stephen Gillies, Kin-Ming Lo, Yan Lan, John Wesolowski
  • Publication number: 20050261229
    Abstract: Disclosed herein are methods and compositions for enhancing the immunogenicity of a preselected protein or peptide antigen in a mammal. Immunogenicity is enhanced by fusing the preselected antigen to an immunoglobulin heavy chain constant region to produce an Fc-antigen fusion protein. The Fc-antigen fusion proteins bind Fc receptors on the surface of antigen presenting cells, thereby targeting the antigen to the antigen presenting cells in the mammal. In addition, disclosed is a family of adjuvants, for example, an Fc-adjuvant fusion protein, for use in combination with the Fc-antigen fusion proteins to enhance or modulate a particular immune response against the preselected antigen.
    Type: Application
    Filed: March 24, 2005
    Publication date: November 24, 2005
    Applicant: EMD Lexigen Research Center Corp.
    Inventors: Stephen Gillies, Kin Lo, John Wesolowski
  • Publication number: 20030105294
    Abstract: Disclosed are methods for the genetic construction and expression of antibody-based fusion proteins with enhanced circulating half-lives. The fusion proteins of the present invention lack the ability to bind to immunoglobulin Fc receptors, either as a consequence of the antibody isotype used for fusion protein construction, or through directed mutagenesis of antibody isotypes that normally bind Fc receptors. The fusion proteins of the present invention may also contain a functional domain capable of binding an immunoglobulin protection receptor.
    Type: Application
    Filed: February 24, 1999
    Publication date: June 5, 2003
    Inventors: STEPHEN GILLIES, KIN-MING LO, YAN LAN, JOHN WESOLOWSKI
  • Patent number: 5880146
    Abstract: Disclosed are chemical agents for modulating certain cellular immune reactions that can lead to autoimmune disorders. By specific modulation, harmful immune reactions can be lessened in severity or even prevented without resorting to potentially dangerous general immune suppression. The described chemical agents inhibit IL-12 induction of the secretion of key immune modulators. The described chemical agents are specific inhibitors of IL-12 induced Th1 immune response.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: March 9, 1999
    Assignee: Fuji ImmunoPharmaceuticals Corporation
    Inventors: Stephen D. Gillies, John Wesolowski